The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection
Scientific title
A Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of ALX 0171 Versus Placebo, in Addition to Standard of Care, in Adults Who Have Undergone Hematopoietic Stem Cell Transplantation and Present With a Respiratory Syncytial Virus Respiratory Tract Infection
Secondary ID [1] 0 0
Secondary ID [2] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Lower Respiratory Tract Infection 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Study type
Description of intervention(s) / exposure
Other interventions - ALX-0171 Dose 1
Other interventions - ALX-0171 Dose 2
Other interventions - Placebo

Experimental: ALX-0171 Dose 1 -

Experimental: ALX-0171 Dose 2 -

Placebo Comparator: Placebo -

Other interventions: ALX-0171 Dose 1
Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days

Other interventions: ALX-0171 Dose 2
Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days

Other interventions: Placebo
Oral inhalation of Placebo once daily for a maximum of 14 days

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Time-weighted average change from baseline in log10 RSV nasal viral load
Timepoint [1] 0 0
From Day 1 to Day 7
Secondary outcome [1] 0 0
Safety as measured by the incidence of treatment-emergent (serious) adverse events
Timepoint [1] 0 0
From Screening to Day 42
Secondary outcome [2] 0 0
Nasal RSV load parameter: time to undetectable shedding
Timepoint [2] 0 0
From Day 1 to Day 42
Secondary outcome [3] 0 0
Clinical stabilization (defined as respiratory rate <25/minute and stable oxygen saturation >92% on room air for at least 12 hours)
Timepoint [3] 0 0
From Day 1 to Day 42
Secondary outcome [4] 0 0
Number of days without oxygen or with oxygen supplementation
Timepoint [4] 0 0
From Day 1 to Day 42
Secondary outcome [5] 0 0
Progression to lower respiratory tract (LRT) disease in subjects presenting with upper respiratory tract infection (URTI) at baseline
Timepoint [5] 0 0
From Day 1 to Day 42
Secondary outcome [6] 0 0
Concentration of ALX-0171 in serum - Measurement of ALX-0171 serum concentration at different time points from baseline until Day 14.
Timepoint [6] 0 0
Day 1 to Day 14
Secondary outcome [7] 0 0
Immunogenicity as measured by the concentration of anti-ALX 0171 antibodies in serum
Timepoint [7] 0 0
From Day 1 to Day 42

Key inclusion criteria
1. Subject has received an HSCT using any conditioning regimen and for any underlying
etiology (i.e., subject has received an autologous or allogeneic HSCT)

2. Subject is clinically diagnosed with RSV infection with new onset or acute worsening

3. Symptoms likely related to RSV infection have appeared within 5 days of screening and
their severity requires initial or maintained hospitalization.

4. Documented RSV infection in the upper respiratory tract (URT)

5. Subject has:

- Diagnosis of RSV lower respiratory tract (LRT) disease or

- Diagnosis of RSV URT disease with high risk of progression to lower respiratory
tract infection (LRTI)

Others as defined in the protocol
Minimum age
18 Years
Maximum age
75 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Subject has clinically significant bacteremia or fungemia within 7 days of screening

2. Subject has clinically significant bacterial, fungal or viral pneumonia

3. Subject presents evidence of shock requiring intensive care unit (ICU) monitoring
and/or vasopressor treatment

4. Subject requires or is expected to require invasive mechanical ventilation or
intensive non-invasive respiratory support. Standard oxygen supplementation up to 6
L/minute is permitted provided it can be interrupted for the duration of study drug

Others as defined in the protocol

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Investigator site - Darlinghurst
Recruitment hospital [2] 0 0
Investigator site - Westmead
Recruitment postcode(s) [1] 0 0
- Darlinghurst
Recruitment postcode(s) [2] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
State/province [1] 0 0
Country [2] 0 0
State/province [2] 0 0

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry

Ethics approval
Ethics application status

Brief summary
The primary objective of the study is to evaluate the antiviral effect and safety of inhaled
ALX-0171 in adults diagnosed with respiratory syncytial virus (RSV) respiratory tract
infection after hematopoietic stem cell transplantation (HSCT).

The secondary objective is to assess the clinical activity, pharmacokinetics (PK), virology,
and immunogenicity of inhaled ALX 0171 in adults diagnosed with RSV respiratory tract
infection after HSCT.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Ablynx Clinical Department
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see